WO1999039756A2 - Supporting material for medicinal purposes - Google Patents
Supporting material for medicinal purposes Download PDFInfo
- Publication number
- WO1999039756A2 WO1999039756A2 PCT/EP1999/000738 EP9900738W WO9939756A2 WO 1999039756 A2 WO1999039756 A2 WO 1999039756A2 EP 9900738 W EP9900738 W EP 9900738W WO 9939756 A2 WO9939756 A2 WO 9939756A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- adhesive
- medical purposes
- carrier material
- purposes according
- backing material
- Prior art date
Links
- 239000000463 material Substances 0.000 title claims abstract description 63
- 239000000853 adhesive Substances 0.000 claims abstract description 113
- 230000001070 adhesive effect Effects 0.000 claims abstract description 84
- 238000009958 sewing Methods 0.000 claims abstract description 23
- 239000012876 carrier material Substances 0.000 claims description 81
- 239000000203 mixture Substances 0.000 claims description 34
- 239000000835 fiber Substances 0.000 claims description 26
- 239000004831 Hot glue Substances 0.000 claims description 23
- 239000004480 active ingredient Substances 0.000 claims description 23
- 239000004745 nonwoven fabric Substances 0.000 claims description 20
- 238000000576 coating method Methods 0.000 claims description 13
- 239000011248 coating agent Substances 0.000 claims description 10
- 239000006260 foam Substances 0.000 claims description 10
- 230000009477 glass transition Effects 0.000 claims description 10
- 230000002787 reinforcement Effects 0.000 claims description 8
- 238000007650 screen-printing Methods 0.000 claims description 8
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 239000010408 film Substances 0.000 claims description 6
- 238000005470 impregnation Methods 0.000 claims description 4
- 230000006835 compression Effects 0.000 claims description 3
- 238000007906 compression Methods 0.000 claims description 3
- 238000007646 gravure printing Methods 0.000 claims description 3
- 238000007639 printing Methods 0.000 claims description 3
- 239000005871 repellent Substances 0.000 claims description 3
- 239000007769 metal material Substances 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- -1 fleece Substances 0.000 description 18
- 239000003570 air Substances 0.000 description 15
- 239000013543 active substance Substances 0.000 description 11
- 229920001400 block copolymer Polymers 0.000 description 11
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 10
- 239000010410 layer Substances 0.000 description 10
- 229920000642 polymer Polymers 0.000 description 10
- 230000035699 permeability Effects 0.000 description 9
- 238000009736 wetting Methods 0.000 description 9
- 239000004952 Polyamide Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 229920002647 polyamide Polymers 0.000 description 8
- 229920000728 polyester Polymers 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 239000012943 hotmelt Substances 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000004014 plasticizer Substances 0.000 description 7
- 239000004744 fabric Substances 0.000 description 6
- 239000001993 wax Substances 0.000 description 6
- 229920000742 Cotton Polymers 0.000 description 5
- 239000004698 Polyethylene Substances 0.000 description 5
- 239000004793 Polystyrene Substances 0.000 description 5
- 229920000297 Rayon Polymers 0.000 description 5
- 206010040880 Skin irritation Diseases 0.000 description 5
- 238000004873 anchoring Methods 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 229930195733 hydrocarbon Natural products 0.000 description 5
- 150000002430 hydrocarbons Chemical class 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 229920000573 polyethylene Polymers 0.000 description 5
- 230000036556 skin irritation Effects 0.000 description 5
- 231100000475 skin irritation Toxicity 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 239000004215 Carbon black (E152) Substances 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 238000003490 calendering Methods 0.000 description 4
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000005187 foaming Methods 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000002557 mineral fiber Substances 0.000 description 4
- 239000011505 plaster Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 229920001169 thermoplastic Polymers 0.000 description 4
- 239000004416 thermosoftening plastic Substances 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000012790 adhesive layer Substances 0.000 description 3
- 239000002390 adhesive tape Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229920001971 elastomer Polymers 0.000 description 3
- 239000003365 glass fiber Substances 0.000 description 3
- 229940127554 medical product Drugs 0.000 description 3
- 210000002346 musculoskeletal system Anatomy 0.000 description 3
- 229920001296 polysiloxane Polymers 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 239000012783 reinforcing fiber Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- 229920000049 Carbon (fiber) Polymers 0.000 description 2
- 239000013032 Hydrocarbon resin Substances 0.000 description 2
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 2
- 208000000112 Myalgia Diseases 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- ZZHLYYDVIOPZBE-UHFFFAOYSA-N Trimeprazine Chemical compound C1=CC=C2N(CC(CN(C)C)C)C3=CC=CC=C3SC2=C1 ZZHLYYDVIOPZBE-UHFFFAOYSA-N 0.000 description 2
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 239000004760 aramid Substances 0.000 description 2
- HJJPJSXJAXAIPN-UHFFFAOYSA-N arecoline Chemical compound COC(=O)C1=CCCN(C)C1 HJJPJSXJAXAIPN-UHFFFAOYSA-N 0.000 description 2
- 229920003235 aromatic polyamide Polymers 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229960002504 capsaicin Drugs 0.000 description 2
- 235000017663 capsaicin Nutrition 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000004917 carbon fiber Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 238000007596 consolidation process Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000010894 electron beam technology Methods 0.000 description 2
- QFXZANXYUCUTQH-UHFFFAOYSA-N ethynol Chemical compound OC#C QFXZANXYUCUTQH-UHFFFAOYSA-N 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 229920006270 hydrocarbon resin Polymers 0.000 description 2
- 229910010272 inorganic material Inorganic materials 0.000 description 2
- OKJPEAGHQZHRQV-UHFFFAOYSA-N iodoform Chemical compound IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
- WFLSCFISQHLEED-UHFFFAOYSA-N isoaminile Chemical compound CN(C)C(C)CC(C(C)C)(C#N)C1=CC=CC=C1 WFLSCFISQHLEED-UHFFFAOYSA-N 0.000 description 2
- 229960004216 isoaminile Drugs 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 229920003052 natural elastomer Polymers 0.000 description 2
- 229920001194 natural rubber Polymers 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- RGOVYLWUIBMPGK-UHFFFAOYSA-N nonivamide Chemical compound CCCCCCCCC(=O)NCC1=CC=C(O)C(OC)=C1 RGOVYLWUIBMPGK-UHFFFAOYSA-N 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 229920005594 polymer fiber Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 230000003014 reinforcing effect Effects 0.000 description 2
- 230000000552 rheumatic effect Effects 0.000 description 2
- 239000005060 rubber Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229920006132 styrene block copolymer Polymers 0.000 description 2
- 229920003051 synthetic elastomer Polymers 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 239000005061 synthetic rubber Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000004753 textile Substances 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- RUVINXPYWBROJD-ONEGZZNKSA-N trans-anethole Chemical compound COC1=CC=C(\C=C\C)C=C1 RUVINXPYWBROJD-ONEGZZNKSA-N 0.000 description 2
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- SLRCCWJSBJZJBV-LXTVHRRPSA-N (-)-Spartein Natural products C1N2CCCC[C@@H]2[C@H]2CN3CCCC[C@@H]3[C@H]1C2 SLRCCWJSBJZJBV-LXTVHRRPSA-N 0.000 description 1
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 1
- FMCGSUUBYTWNDP-ONGXEEELSA-N (1R,2S)-2-(dimethylamino)-1-phenyl-1-propanol Chemical compound CN(C)[C@@H](C)[C@H](O)C1=CC=CC=C1 FMCGSUUBYTWNDP-ONGXEEELSA-N 0.000 description 1
- IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- MXOAEAUPQDYUQM-QMMMGPOBSA-N (S)-chlorphenesin Chemical compound OC[C@H](O)COC1=CC=C(Cl)C=C1 MXOAEAUPQDYUQM-QMMMGPOBSA-N 0.000 description 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
- ZWLMLVIUWRUDBD-BTJKTKAUSA-N (z)-but-2-enedioate;3-(2-methoxy-10h-phenothiazin-10-ium-10-yl)propyl-dimethylazanium Chemical compound OC(=O)\C=C/C(O)=O.C1=CC=C2N(CCCN(C)C)C3=CC(OC)=CC=C3SC2=C1 ZWLMLVIUWRUDBD-BTJKTKAUSA-N 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- JWDYCNIAQWPBHD-UHFFFAOYSA-N 1-(2-methylphenyl)glycerol Chemical compound CC1=CC=CC=C1OCC(O)CO JWDYCNIAQWPBHD-UHFFFAOYSA-N 0.000 description 1
- KVHHQGIIZCJATJ-UHFFFAOYSA-N 1-(4-chlorophenyl)-4-(dimethylamino)-2,3-dimethyl-2-butanol Chemical compound CN(C)CC(C)C(C)(O)CC1=CC=C(Cl)C=C1 KVHHQGIIZCJATJ-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- YREYLAVBNPACJM-UHFFFAOYSA-N 2-(tert-butylamino)-1-(2-chlorophenyl)ethanol Chemical compound CC(C)(C)NCC(O)C1=CC=CC=C1Cl YREYLAVBNPACJM-UHFFFAOYSA-N 0.000 description 1
- XILVEPYQJIOVNB-UHFFFAOYSA-N 2-[3-(trifluoromethyl)anilino]benzoic acid 2-(2-hydroxyethoxy)ethyl ester Chemical compound OCCOCCOC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 XILVEPYQJIOVNB-UHFFFAOYSA-N 0.000 description 1
- IVQOFBKHQCTVQV-UHFFFAOYSA-N 2-hydroxy-2,2-diphenylacetic acid 2-(diethylamino)ethyl ester Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCCN(CC)CC)C1=CC=CC=C1 IVQOFBKHQCTVQV-UHFFFAOYSA-N 0.000 description 1
- MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 description 1
- IKQUUYYDRTYXAP-UHFFFAOYSA-N 3-methylpenta-1,4-diene Chemical compound C=CC(C)C=C IKQUUYYDRTYXAP-UHFFFAOYSA-N 0.000 description 1
- PFEOZHBOMNWTJB-UHFFFAOYSA-N 3-methylpentane Chemical compound CCC(C)CC PFEOZHBOMNWTJB-UHFFFAOYSA-N 0.000 description 1
- KFZXVMNBUMVKLN-UHFFFAOYSA-N 4-chloro-5-methyl-2-propan-2-ylphenol Chemical compound CC(C)C1=CC(Cl)=C(C)C=C1O KFZXVMNBUMVKLN-UHFFFAOYSA-N 0.000 description 1
- WFJIVOKAWHGMBH-UHFFFAOYSA-N 4-hexylbenzene-1,3-diol Chemical compound CCCCCCC1=CC=C(O)C=C1O WFJIVOKAWHGMBH-UHFFFAOYSA-N 0.000 description 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- WNCAVNGLACHSRZ-KAMYIIQDSA-N Allithiamine Chemical compound C=CCSSC(/CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N WNCAVNGLACHSRZ-KAMYIIQDSA-N 0.000 description 1
- WNCAVNGLACHSRZ-UHFFFAOYSA-N Allithiamine Natural products C=CCSSC(CCO)=C(C)N(C=O)CC1=CN=C(C)N=C1N WNCAVNGLACHSRZ-UHFFFAOYSA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241001465356 Atropa belladonna Species 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- GXGJIOMUZAGVEH-UHFFFAOYSA-N Chamazulene Chemical compound CCC1=CC=C(C)C2=CC=C(C)C2=C1 GXGJIOMUZAGVEH-UHFFFAOYSA-N 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- OGDVEMNWJVYAJL-LEPYJNQMSA-N Ethyl morphine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OCC OGDVEMNWJVYAJL-LEPYJNQMSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- OGDVEMNWJVYAJL-UHFFFAOYSA-N Ethylmorphine Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OCC OGDVEMNWJVYAJL-UHFFFAOYSA-N 0.000 description 1
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- 229920002633 Kraton (polymer) Polymers 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
- AJXPJJZHWIXJCJ-UHFFFAOYSA-N Methsuximide Chemical compound O=C1N(C)C(=O)CC1(C)C1=CC=CC=C1 AJXPJJZHWIXJCJ-UHFFFAOYSA-N 0.000 description 1
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 1
- SIDLZWOQUZRBRU-UHFFFAOYSA-N Methyprylon Chemical compound CCC1(CC)C(=O)NCC(C)C1=O SIDLZWOQUZRBRU-UHFFFAOYSA-N 0.000 description 1
- 206010050031 Muscle strain Diseases 0.000 description 1
- 206010049816 Muscle tightness Diseases 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- FMCGSUUBYTWNDP-UHFFFAOYSA-N N-Methylephedrine Natural products CN(C)C(C)C(O)C1=CC=CC=C1 FMCGSUUBYTWNDP-UHFFFAOYSA-N 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 1
- ISFHAYSTHMVOJR-UHFFFAOYSA-N Phenindamine Chemical compound C1N(C)CCC(C2=CC=CC=C22)=C1C2C1=CC=CC=C1 ISFHAYSTHMVOJR-UHFFFAOYSA-N 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- QZVCTJOXCFMACW-UHFFFAOYSA-N Phenoxybenzamine Chemical compound C=1C=CC=CC=1CN(CCCl)C(C)COC1=CC=CC=C1 QZVCTJOXCFMACW-UHFFFAOYSA-N 0.000 description 1
- WLWFNJKHKGIJNW-UHFFFAOYSA-N Phensuximide Chemical compound O=C1N(C)C(=O)CC1C1=CC=CC=C1 WLWFNJKHKGIJNW-UHFFFAOYSA-N 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- IFFPICMESYHZPQ-UHFFFAOYSA-N Prenylamine Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)CCNC(C)CC1=CC=CC=C1 IFFPICMESYHZPQ-UHFFFAOYSA-N 0.000 description 1
- AUVVAXYIELKVAI-UHFFFAOYSA-N SJ000285215 Natural products N1CCC2=CC(OC)=C(OC)C=C2C1CC1CC2C3=CC(OC)=C(OC)C=C3CCN2CC1CC AUVVAXYIELKVAI-UHFFFAOYSA-N 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- 208000008765 Sciatica Diseases 0.000 description 1
- 229920002334 Spandex Polymers 0.000 description 1
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical group ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- TZZAKSLHHIJRLL-UHFFFAOYSA-N Vanillinsaeure-amid Natural products COC1=CC(C(N)=O)=CC=C1O TZZAKSLHHIJRLL-UHFFFAOYSA-N 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000037374 absorbed through the skin Effects 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 229960003216 aceclidine Drugs 0.000 description 1
- WRJPSSPFHGNBMG-UHFFFAOYSA-N acetic acid 1-azabicyclo[2.2.2]octan-3-yl ester Chemical compound C1CC2C(OC(=O)C)CN1CC2 WRJPSSPFHGNBMG-UHFFFAOYSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 230000001171 adenosinetriphosphoric effect Effects 0.000 description 1
- 239000004840 adhesive resin Substances 0.000 description 1
- 229920006223 adhesive resin Polymers 0.000 description 1
- 229960003790 alimemazine Drugs 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- SLRCCWJSBJZJBV-UHFFFAOYSA-N alpha-isosparteine Natural products C1N2CCCCC2C2CN3CCCCC3C1C2 SLRCCWJSBJZJBV-UHFFFAOYSA-N 0.000 description 1
- NFHVTCJKAHYEQN-UHFFFAOYSA-N amfetaminil Chemical compound C=1C=CC=CC=1C(C#N)NC(C)CC1=CC=CC=C1 NFHVTCJKAHYEQN-UHFFFAOYSA-N 0.000 description 1
- 229950000762 amfetaminil Drugs 0.000 description 1
- 229920006125 amorphous polymer Polymers 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 229960003116 amyl nitrite Drugs 0.000 description 1
- 229940011037 anethole Drugs 0.000 description 1
- 239000010692 aromatic oil Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 238000001266 bandaging Methods 0.000 description 1
- 229960001498 benactyzine Drugs 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 229960003328 benzoyl peroxide Drugs 0.000 description 1
- 229940036350 bisabolol Drugs 0.000 description 1
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000746 body region Anatomy 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- DLNKOYKMWOXYQA-IONNQARKSA-N cathine Chemical compound C[C@H](N)[C@@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-IONNQARKSA-N 0.000 description 1
- 229960003609 cathine Drugs 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- PMRJYBALQVLLSJ-UHFFFAOYSA-N chamazulene Natural products CCC1=CC2=C(C)CCC2=CC=C1 PMRJYBALQVLLSJ-UHFFFAOYSA-N 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 229940031956 chlorothymol Drugs 0.000 description 1
- 229960003993 chlorphenesin Drugs 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 description 1
- 229960001747 cinchocaine Drugs 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 229940021231 clearskin Drugs 0.000 description 1
- 229960002881 clemastine Drugs 0.000 description 1
- 229960002735 clobutinol Drugs 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000004567 concrete Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- HFXKQSZZZPGLKQ-UHFFFAOYSA-N cyclopentamine Chemical compound CNC(C)CC1CCCC1 HFXKQSZZZPGLKQ-UHFFFAOYSA-N 0.000 description 1
- 229960003263 cyclopentamine Drugs 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- SOYKEARSMXGVTM-HNNXBMFYSA-N dexchlorpheniramine Chemical compound C1([C@H](CCN(C)C)C=2N=CC=CC=2)=CC=C(Cl)C=C1 SOYKEARSMXGVTM-HNNXBMFYSA-N 0.000 description 1
- 229960001882 dexchlorpheniramine Drugs 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- OWQIUQKMMPDHQQ-UHFFFAOYSA-N dimethocaine Chemical compound CCN(CC)CC(C)(C)COC(=O)C1=CC=C(N)C=C1 OWQIUQKMMPDHQQ-UHFFFAOYSA-N 0.000 description 1
- 229950010160 dimethocaine Drugs 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- MSYUMPGNGDNTIQ-UHFFFAOYSA-N dixyrazine Chemical compound C12=CC=CC=C2SC2=CC=CC=C2N1CC(C)CN1CCN(CCOCCO)CC1 MSYUMPGNGDNTIQ-UHFFFAOYSA-N 0.000 description 1
- 229960005146 dixyrazine Drugs 0.000 description 1
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- AUVVAXYIELKVAI-CKBKHPSWSA-N emetine Chemical compound N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@@H]1CC AUVVAXYIELKVAI-CKBKHPSWSA-N 0.000 description 1
- 229960002694 emetine Drugs 0.000 description 1
- SLWGJZPKHAXZQL-UHFFFAOYSA-N emylcamate Chemical compound CCC(C)(CC)OC(N)=O SLWGJZPKHAXZQL-UHFFFAOYSA-N 0.000 description 1
- 229960000650 emylcamate Drugs 0.000 description 1
- JPGQOUSTVILISH-UHFFFAOYSA-N enflurane Chemical compound FC(F)OC(F)(F)C(F)Cl JPGQOUSTVILISH-UHFFFAOYSA-N 0.000 description 1
- 229960000305 enflurane Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- HAPOVYFOVVWLRS-UHFFFAOYSA-N ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 description 1
- 229960002767 ethosuximide Drugs 0.000 description 1
- 229960004578 ethylmorphine Drugs 0.000 description 1
- 229960001493 etofenamate Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 229960003258 hexylresorcinol Drugs 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 230000000544 hyperemic effect Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 239000012784 inorganic fiber Substances 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910001867 inorganic solvent Inorganic materials 0.000 description 1
- 239000003049 inorganic solvent Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
- 229960000201 isosorbide dinitrate Drugs 0.000 description 1
- 229940116298 l- malic acid Drugs 0.000 description 1
- 238000010030 laminating Methods 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229960003861 mephenesin Drugs 0.000 description 1
- 229960003729 mesuximide Drugs 0.000 description 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
- 229960001797 methadone Drugs 0.000 description 1
- 238000010327 methods by industry Methods 0.000 description 1
- 229950008620 methopromazine Drugs 0.000 description 1
- RFKMCNOHBTXSMU-UHFFFAOYSA-N methoxyflurane Chemical compound COC(F)(F)C(Cl)Cl RFKMCNOHBTXSMU-UHFFFAOYSA-N 0.000 description 1
- 229960002455 methoxyflurane Drugs 0.000 description 1
- 229960002221 methylephedrine Drugs 0.000 description 1
- QXLPXWSKPNOQLE-UHFFFAOYSA-N methylpentynol Chemical compound CCC(C)(O)C#C QXLPXWSKPNOQLE-UHFFFAOYSA-N 0.000 description 1
- 229960001344 methylphenidate Drugs 0.000 description 1
- 229960000316 methyprylon Drugs 0.000 description 1
- MJFJKKXQDNNUJF-UHFFFAOYSA-N metixene Chemical compound C1N(C)CCCC1CC1C2=CC=CC=C2SC2=CC=CC=C21 MJFJKKXQDNNUJF-UHFFFAOYSA-N 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 239000012764 mineral filler Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 208000015001 muscle soreness Diseases 0.000 description 1
- CSDTZUBPSYWZDX-UHFFFAOYSA-N n-pentyl nitrite Chemical compound CCCCCON=O CSDTZUBPSYWZDX-UHFFFAOYSA-N 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- NCYVXEGFNDZQCU-UHFFFAOYSA-N nikethamide Chemical compound CCN(CC)C(=O)C1=CC=CN=C1 NCYVXEGFNDZQCU-UHFFFAOYSA-N 0.000 description 1
- 229960003226 nikethamide Drugs 0.000 description 1
- 229910052756 noble gas Inorganic materials 0.000 description 1
- 150000002835 noble gases Chemical class 0.000 description 1
- 229960004036 nonivamide Drugs 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000012766 organic filler Substances 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- RUVINXPYWBROJD-UHFFFAOYSA-N para-methoxyphenyl Natural products COC1=CC=C(C=CC)C=C1 RUVINXPYWBROJD-UHFFFAOYSA-N 0.000 description 1
- WEYVCQFUGFRXOM-UHFFFAOYSA-N perazine Chemical compound C1CN(C)CCN1CCCN1C2=CC=CC=C2SC2=CC=CC=C21 WEYVCQFUGFRXOM-UHFFFAOYSA-N 0.000 description 1
- 229960002195 perazine Drugs 0.000 description 1
- 229960000482 pethidine Drugs 0.000 description 1
- 229960003534 phenindamine Drugs 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 229960003418 phenoxybenzamine Drugs 0.000 description 1
- 229960004227 phensuximide Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- ULSIYEODSMZIPX-UHFFFAOYSA-N phenylethanolamine Chemical compound NCC(O)C1=CC=CC=C1 ULSIYEODSMZIPX-UHFFFAOYSA-N 0.000 description 1
- 229950006768 phenylethanolamine Drugs 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- MDCSSISSJDDFCV-WCCKRBBISA-N piperazine (2S)-pyrrolidine-2-carboxylic acid Chemical compound C1CNCCN1.OC(=O)[C@@H]1CCCN1 MDCSSISSJDDFCV-WCCKRBBISA-N 0.000 description 1
- FWWDFDMCZLOXQI-UHFFFAOYSA-N pivhydrazine Chemical compound CC(C)(C)C(=O)NNCC1=CC=CC=C1 FWWDFDMCZLOXQI-UHFFFAOYSA-N 0.000 description 1
- 229950008099 pivhydrazine Drugs 0.000 description 1
- 229920006149 polyester-amide block copolymer Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920002742 polystyrene-block-poly(ethylene/propylene) -block-polystyrene Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229960001989 prenylamine Drugs 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- CDOZDBSBBXSXLB-UHFFFAOYSA-N profenamine Chemical compound C1=CC=C2N(CC(C)N(CC)CC)C3=CC=CC=C3SC2=C1 CDOZDBSBBXSXLB-UHFFFAOYSA-N 0.000 description 1
- 229960002262 profenamine Drugs 0.000 description 1
- 229960003910 promethazine Drugs 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 239000002964 rayon Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003902 salicylic acid esters Chemical class 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 229920006126 semicrystalline polymer Polymers 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000004759 spandex Substances 0.000 description 1
- SLRCCWJSBJZJBV-AJNGGQMLSA-N sparteine Chemical compound C1N2CCCC[C@H]2[C@@H]2CN3CCCC[C@H]3[C@H]1C2 SLRCCWJSBJZJBV-AJNGGQMLSA-N 0.000 description 1
- 229960001945 sparteine Drugs 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 238000005979 thermal decomposition reaction Methods 0.000 description 1
- 229960002784 thioridazine Drugs 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 229960004605 timolol Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229960003741 tranylcypromine Drugs 0.000 description 1
- ZEWQUBUPAILYHI-UHFFFAOYSA-N trifluoperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 description 1
- 229960002324 trifluoperazine Drugs 0.000 description 1
- IRYJRGCIQBGHIV-UHFFFAOYSA-N trimethadione Chemical compound CN1C(=O)OC(C)(C)C1=O IRYJRGCIQBGHIV-UHFFFAOYSA-N 0.000 description 1
- 229960004453 trimethadione Drugs 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 229940048102 triphosphoric acid Drugs 0.000 description 1
- 229960000859 tulobuterol Drugs 0.000 description 1
- PRBORDFJHHAISJ-UHFFFAOYSA-N tybamate Chemical compound CCCCNC(=O)OCC(C)(CCC)COC(N)=O PRBORDFJHHAISJ-UHFFFAOYSA-N 0.000 description 1
- 229960002560 tybamate Drugs 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- 239000002966 varnish Substances 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 239000002759 woven fabric Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
- A61F13/0203—Adhesive bandages or dressings with fluid retention members
- A61F13/0223—Adhesive bandages or dressings with fluid retention members characterized by parametric properties of the fluid retention layer, e.g. absorbency, wicking capacity, liquid distribution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
- A61F13/0203—Adhesive bandages or dressings with fluid retention members
- A61F13/0226—Adhesive bandages or dressings with fluid retention members characterised by the support layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
- A61F13/0246—Adhesive bandages or dressings characterised by the skin-adhering layer
- A61F13/025—Adhesive bandages or dressings characterised by the skin-adhering layer having a special distribution arrangement of the adhesive
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
- A61F13/0246—Adhesive bandages or dressings characterised by the skin-adhering layer
- A61F13/0256—Adhesive bandages or dressings characterised by the skin-adhering layer characterized by the parametric properties of the adhesive
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/58—Adhesives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
Definitions
- the invention relates to a carrier material for medical purposes, preferably a medical plaster, which is coated at least on one side over the entire surface or partially with a doped adhesive.
- carrier materials Numerous materials based on foils, woven fabrics, knitted fabrics, fleece, gel or foam are already known as carrier materials for medical purposes and are also used in practice.
- the materials which are often still coated with a self-adhesive, must be compatible with the skin, generally permeable to air and water vapor, and be easy to mold and conform. Because of these requirements, a carrier that is as thin or soft as possible is often preferred. Sufficient strength and, if necessary, limited elasticity are also required for the handling and use of the carrier materials. Furthermore, the carrier material should have sufficient strength and low elasticity even after it has been soaked.
- Thin supports especially those made of nonwovens, are well permeable to air and water vapor. However, their strength is too low and their elongation too high for certain applications. Furthermore, the padding effect is not sufficient for these inexpensive carriers.
- inelastic supports with high strength in the direction of stress are required. This is achieved by using woven or knitted fabrics, usually made of cotton or viscose.
- carrier materials with a correspondingly high basis weight are cost-intensive.
- a high degree of conformability and adaptability can only be achieved with fabrics with lower strength. However, these generally point then too little padding under stress, which is undesirable for the application.
- the bandages listed may lose strength or become more elastic when drenched. This is also undesirable for use and has so far been compensated for by a more frequent dressing change, which on the other hand is cost-intensive.
- the AU 73555/74 for example, describes a carrier material reinforced with glass threads for medical foam-based applications.
- DE 44 42 092 and DE G 94 01 037 describe adhesive tapes based on sewing fleece, which are partially coated on the back of the carrier. Such tapes are preferably used in cable banding.
- DE 44 42 093 is also based on the use of a nonwoven as a carrier for an adhesive tape, here a transverse fiber nonwoven reinforced by the formation of stitches from the fibers of the nonwoven is described.
- DE 44 42 507 also discloses an adhesive tape for cable bandaging, but it is based on so-called Kunit or Multikunit fleece.
- Kunit or Multikunit fleece the use or special suitability of these carrier materials for medical purposes cannot be derived from the documents mentioned.
- doping with active substances is not mentioned.
- No. 4,773,238 describes a longitudinally sewn-over fiber fleece, the sewing seams not to have more than 20% by weight, based on the weight of the entire fleece.
- the use according to the invention as an insert for filters in dust filtering is proposed.
- No. 4,967,740 generally discloses carrier materials for use in medical care, which are produced in a 1-step process. In this process, the carrier is impregnated with an elastomer and a release solution at the same time. In this way, the material can be presented on a roll without release paper. Doping with active substances not mentioned.
- Transdermal therapeutic systems are dosage forms of medication that deliver one or more drugs to the skin at their application site over a defined period of time. A distinction is made between systemic and locally effective dosage forms.
- the active ingredient gets into the bloodstream by diffusion through the skin and can work throughout the body.
- Dosage forms with a local effect on the other hand, only act on the applied areas. The active ingredient remains in the skin or in the layers underneath.
- Strongly adhesive plasters are usually coated over their entire surface with a rubber adhesive. These adhesives then allow secure bonding, for example in critical areas such as joints, over a period of several days. However, sticking such products to the skin shows clear skin irritation and mechanical stress on the skin after detachment. The glue can only be removed without pain without aids.
- the aforementioned adhesive compositions can be pressure-sensitive self-adhesive compositions, the compositions for processing being able to be present in a carrier matrix.
- Common organic or inorganic solvents or dispersants are understood as carrier matrix. Systems without a carrier matrix are called 100% systems and are also not unknown. They are processed in the elastic or thermoplastic state. A common processing method is the melt.
- hotmelt adhesives have also been described in the prior art. They are based on natural or synthetic rubbers and / or other synthetic polymers.
- An advantage of the 100% systems is that, in terms of process engineering, they remove the carrier matrix, i.e. the aid is avoided, which increases processing productivity and at the same time reduces machine and energy expenditure. In this way, remaining residues of the carrier matrix are reduced. This in turn favors the lowering of the allergenic potential.
- the advantage of the grid-like application is that the adhesive materials are permeable to air and water vapor and, as a rule, are easily removable if the carrier material is appropriately porous.
- a disadvantage of these products lies in the fact that if the surface of the adhesive layer, which is impermeable per se, is too high, the permeability to air and water vapor decreases accordingly, the consumption of adhesive mass increases and the adhesive properties suffer if the surface area of the adhesive layer is poor, ie the product dissolves, especially with heavy, textile substrates, too light from the surface.
- the adhesive of the patch can be used as the matrix containing the active ingredient.
- hotmelt adhesives have also already been proposed for this, for example in EP-A 663 431, EP-A 452 034, EP-A 305 757, DE-OS 43 10 012, DE-OS 42 22 334 and DE- C 42 24 325.
- the active substances listed here, if they have been named, are systemically active. Use of the carrier according to the invention is not described.
- active substance-containing plasters are the active substance plasters which promote blood circulation and belong to the group of locally active therapeutic systems. The use of such plasters is indicated for the treatment of rheumatic complaints, sciatica, lumbago, neck stiffness, shoulder-arm pain as well as muscle tension and strains, muscle soreness or muscle, joint and nerve pain in the area of the musculoskeletal system.
- Capsaicin, Belladonna and nonivamide are known active ingredients of such plasters that have a local effect on the circulation. Because of their application to the musculoskeletal system, they usually have to stick very well.
- the patches are usually coated over their entire surface with a resin-rubber adhesive which contains the active ingredient.
- WO 94/02123 describes an active ingredient plaster based on pressure-sensitive hotmelt compositions which contains low-melting and / or highly volatile active ingredients in a concentration of 2.5% by weight to 25% by weight.
- the use of the carrier according to the invention is not described.
- EP 0 663 431 A2, EP 0 443 759 A3, EP 0 452 034 A2 and US 5,371, 128 describe uses of pressure-sensitive hotmelt pressure-sensitive adhesives on a silicone basis with various additives and in different designs. Use of the carrier according to the invention is not described.
- EP 0 439 180 describes an active ingredient patch for the administration of tulobuterol.
- EP 0 305 757 describes an active ingredient patch for the administration of nicotine.
- EP 0 305 758 describes an active ingredient patch for the administration of nitroglycerin.
- EP 0 305 756 describes an adhesive of substances and their production and use. Use of the carrier according to the invention is not described.
- WO 96/22083 shows a polyisobutylene adhesive for transdermal purposes, which has a tackifier with a high glass transition point. Use of the carrier according to the invention is not described.
- JP 07-196505 describes an administration of inkomethacin in hotmelt PSAs. Here, a polyethylene foam is used as the carrier material. Use of the carrier according to the invention is not described.
- the object of the invention was to provide a nonwoven-based carrier material which has been coated with a doped adhesive and is suitable for medical requirements and which, moreover, does not have the disadvantages known from the prior art.
- a nonwoven fabric sewn by means of sewing threads is used as a backing material for medical purposes, the number of seams on the nonwoven fabric advantageously being at least 3 / cm, preferably 5 / cm to 50 / cm.
- the maximum tensile force of the carrier material amounts to at least 10 N / cm, preferably 20 to 450 N / cm, particularly preferably 30 to 250 N / cm, and the carrier material is coated at least on one side with a doped adhesive in whole or in part.
- the sewing threads preferably have a water absorption of less than 30%, particularly preferably less than 20%.
- the water absorption can be regenerated by the air humidity.
- polymeric fibers made of polypropylene, polyester, polyamide, aramid or polyethylene and also mineral fibers such as glass fibers or carbon fibers can advantageously be used as materials for the sewing threads. Threads or mixed twists, in particular siromix, can also be used. Mixed fiber threads, yarns or twists can also be used for special applications.
- the sewing threads can be at least partially colored in order to make the carrier material more visually appealing.
- the sewing thread can also be elastic for special applications. This then regenerates an elastic base support with an elongation of up to 250% at a load of 10 N / cm.
- a polyamide thread (Lycra®, DuPont) may be mentioned here.
- Such a carrier material produces a compression force of 0.2 N / cm to 10 N / cm at an elongation of 20% to 70% and is used in compression technology.
- a fleece is used as a carrier material for medical purposes.
- the fleece is reinforced by the formation of seams, which are formed by stitches from the fibers of the fleece, the number of seams on the fleece advantageously being at least 3 / cm, preferably 5 / cm to 50 / cm.
- the maximum tensile force of the backing material is at least 10 N / cm, preferably 20 to 450 N / cm, particularly preferably 50 to 250 N / cm, and the backing material is partially or fully coated on at least one side with a doped adhesive.
- the carrier materials are based on known nonwovens, which are mechanically consolidated, by sewing on with separate threads or by stitching.
- the nonwoven thread sewing fabrics result.
- a nonwoven fabric is presented, which can be cross-paneled, for example, and sewn on with separate threads in fringed or tricot layers.
- a cross-paneled fleece is preferably also presented.
- needles pull fibers out of the fleece itself and form them into stitches, with seams being created in fringe layers.
- This nonwoven knitted fabric is known under the name "Malivlies”, also from the Malimo company.
- nonwovens have longitudinal seams, the orientation of the sewing threads being oriented according to the stress on the carrier material in use.
- All organic and inorganic fiber materials on a natural and synthetic basis can generally be used as starting materials for the nonwoven fabric.
- examples include viscose, cotton, silk, polypropylene, polyester, polyurethane, polyamide, aramid or polyethylene, as well as mineral fibers such as glass fibers or carbon fibers.
- the present invention is not limited to the materials mentioned, but a large number of further fibers can be used for the formation of nonwovens.
- the fibers used to form the fleece preferably have a water retention capacity of more than 0.5%, preferably between 2 to 70%, particularly preferably between 3 and 50%.
- the carrier material has a maximum tensile force elongation of less than 40%, preferably less than 15%, particularly preferably less than 10%.
- a nonwoven fabric sewn by means of sewing threads this is achieved, on the one hand, by using a sewing thread material with a high modulus of elasticity, and, on the other hand, by using a sewing stitch which ensures that the sewing thread layer is as stretched as possible.
- Advantageous material combinations are, for example, sewing threads made of high-strength polymer fibers such as polyamide, polyester, highly stretched polyethylene or mineral fibers such as glass and non-woven materials such as cotton or wool.
- the material of the fleece provided must be selected accordingly; the same applies to the sewing stitch.
- the carrier material should have a weight per unit area of up to 500 g / m 2 , preferably 10 to 350 g / m 2 .
- the backing material can be torn by hand perpendicular to the orientation of the seams and / or in the direction of the seams. This is used when the carrier material according to the invention is wound onto a roll on itself.
- this tearability is not necessary. This can be pre-cut plasters.
- the carrier material can be reinforced with one or more threads made of monofilament, multifilament, staple fiber yarn or spun fiber yarn and / or with oriented high-strength fibers, the threads and / or fibers in particular having a strength of at least 40 cN ⁇ ex. It is also possible to use twisted or mixed twisted yarns, in particular siromixed twins. Mixed fiber threads, yarns or twists can also be used for special applications. This can be, for example, wrapping yarns or special staple fiber wrapping yarns.
- the reinforcing fibers or threads can consist of organic or inorganic materials, for example and preferably consist of glass, carbon, polyester or special polyamides. Furthermore, the reinforcing fibers can be at least partially colored in order to make the carrier material more visually appealing. In this way it is easily possible to differentiate the reinforced beams optically. Dyed glass or polymer threads are particularly suitable for this.
- the addition of high-strength fibers or threads with a maximum tensile force of more than 40 cN / tex shows a maximum tensile force of more than 50 N / cm and an elongation of less than 25% with a basis weight of less than 140 g / m 2 .
- the number of threads or high-strength fibers attached or introduced depends primarily on the intended use and the desired maximum tensile force and elongation at maximum tensile strength of the carrier material, its own nature and the respective strength of the fibers and threads themselves and can therefore vary within relatively wide limits.
- Advantageous material combinations are, for example, reinforcing threads or fibers made of high-strength polymer fibers such as polyamide, polyester, highly stretched polyethylene or mineral fibers such as glass and nonwoven materials such as cotton or cellulose.
- high-strength polymer fibers such as polyamide, polyester, highly stretched polyethylene or mineral fibers such as glass and nonwoven materials such as cotton or cellulose.
- the reinforcements are preferably inserted in a targeted manner in accordance with the direction of stress of the carrier material, i.e. longitudinal. However, if this is more expedient, they can also run additionally or only in the transverse or oblique direction or, for example, in a curved, spiral or zigzag shape or randomly.
- the carrier material can be torn by hand perpendicular to the orientation of the reinforcement and / or in the direction of the reinforcement.
- Different active substances can preferably be contained in the adhesive, the amount of the active substance or active substances in the adhesive preferably being between 0.01 and approximately 60% by weight, preferably 0.1 to 20% by weight.
- active ingredients in connection with the present invention includes chemical elements, organic and inorganic compounds that migrate out of the constituents of a generic adhesive containing them can and thereby produce a desired effect, understood.
- Human and veterinary medicine are of particular importance among the fields of application of the adhesive according to the invention, an embodiment of the invention in plaster form being particularly preferred here.
- Typical substances that can be administered via devices manufactured according to the invention are:
- Aceclidine, amfetaminil, amfetamine, amyl nitrite, apophedrine, atebrin, alpostadil, azulene, arecoline, anethole, amylene hydrate, acetylcholine, acridine, adenosine triphosphoric acid, L-malic acid, alimemazine, allithiamine, azophyllate, ethynol isocyanin alginolamine, ethynol isothiocyanin , benzoyl peroxide, benzyl alcohol, bisabolol, Bisnore- phedrin, Butacetoluid, benactyzine, camphor, colecalciferol, chloral hydrate, clemastine, chlorobutanol, capsaicin, cyclopentamine, clobutinol, chamazulene, dimethocaine, codeine, chloropromazine, quinine, chloro
- the active ingredients are preferably distributed in the adhesive in commercially available homogenizers such as mixers, kneaders, rolling mills or screw systems.
- the active ingredient can be added to the completely prepared adhesive.
- the active ingredient can also be incorporated into an intermediate stage or into the starting mixture.
- Self-adhesive compositions based on natural and synthetic rubbers and other synthetic polymers such as acrylates, methacrylates, polyurethanes, polyolefins, polyvinyl derivatives, polyesters or silicones with appropriate additives such as adhesive resins, plasticizers, stabilizers and other auxiliaries can be used as adhesive compositions, if necessary.
- the adhesive composition can furthermore contain polymers which form a physically or chemically crosslinked gel.
- Thermoplastic hot melt adhesives in particular have advantageous properties and are favored for production reasons.
- the softening point should be higher than 50 ° C, since the application temperature for the coating is generally at least 90 ° C, preferably between 120 ° C and 150 ° C or 180 ° C and 220 ° C for special adhesives such as silicones. Post-crosslinking by high-energy radiation such as UV or electron beams may be appropriate.
- Preferred hotmelt adhesives based on block copolymers are distinguished by their wide range of possible variations, because the required functional bonding to the skin is also achieved by the targeted lowering of the glass transition temperature of the self-adhesive composition as a result of the selection of the tackifiers, the plasticizers and the polymer molecule size and the molecular distribution of the insert components guaranteed at critical points of the human musculoskeletal system.
- the high shear strength of the hot melt adhesive is achieved through the high cohesiveness of the polymer.
- the good grip tack results from the range of tackifiers and plasticizers used.
- the hotmelt adhesive is preferably based on block copolymers, in particular AB, ABA block copolymers or mixtures thereof.
- the hard phase A is primarily polystyrene or its derivatives
- the soft phase B contains ethylene, propylene, butylene, butadiene, isoprene or mixtures thereof, particularly preferably ethylene and butylene or mixtures thereof.
- Polystyrene blocks can, however, also be present in the soft phase B, namely up to 20% by weight. However, the total styrene content should always be less than 35% by weight. Styrene fractions between 5% and 30% are preferred, since a lower styrene fraction makes the adhesive more supple.
- the targeted blending of di-block and tri-block copolymers is advantageous, a proportion of di-block copolymers of less than 80% by weight being preferred.
- the hot-melt adhesive has the following composition:
- tackifiers such as oils, waxes, resins and / or mixtures thereof, preferably mixtures of resins and oils, less than 60% by weight of plasticizer, less than 15% by weight of additives, less than 5% by weight of stabilizers, less than 60% by weight of active ingredient
- the aliphatic or aromatic oils, waxes and resins used as tackifiers are preferably hydrocarbon oils, waxes and resins, the oils, such as paraffinic hydrocarbon oils, or the waxes, such as paraffinic hydrocarbon waxes, having a favorable effect on the skin adhesion due to their consistency.
- the oils, such as paraffinic hydrocarbon oils, or the waxes, such as paraffinic hydrocarbon waxes having a favorable effect on the skin adhesion due to their consistency.
- Medium or long chain fatty acids and / or their esters are used as plasticizers. These additives serve to adjust the adhesive properties and the stability. If necessary, further stabilizers and other auxiliaries are used.
- the self-adhesive has a softening point above 70 ° C., preferably 80 ° C. to 140 ° C.
- the hotmelt self-adhesive compositions are preferably set so that they have a dynamic-complex glass transition temperature of less than 15 ° C., preferably from 3 ° C. to -30 ° C., very particularly preferably from -3 ° C., at a frequency of 0.1 rad / s down to - 25 ° C.
- the hot melt adhesive should have a high tack.
- the functionally adapted adhesive strength on the skin and on the back of the carrier should be present. Furthermore, so that there is no slipping, a high shear strength of the hot-melt adhesive is necessary.
- the necessary functional bonding with the skin and the back of the carrier is achieved.
- the high shear strength of the adhesive used here is achieved through the high coherency of the block copolymer.
- the good tackiness results from the range of tackifiers and plasticizers used.
- the product properties such as stickiness, glass transition temperature and shear stability can be quantified well with the help of a dynamic mechanical frequency measurement.
- a shear stress controlled rheometer is used.
- the results of this measurement method provide information about the physical properties of a substance by taking the viscoelastic component into account.
- the self-adhesive composition is set in vibration between two plane-parallel plates with variable frequencies and low deformation (linear viscoelastic area).
- a high numerical value means better grip and poorer shear stability.
- the glass transition temperature is the temperature at which amorphous or semi-crystalline polymers change from the liquid or rubber-elastic state to the hard-elastic or glassy state or vice versa (Römpp Chemie-Lexikon, 9th edition, volume 2, page 1587, Georg Thieme Verlag Stuttgart - New York , 1990). It corresponds to the maximum of the temperature function at a given frequency.
- a relatively low glass transition point is particularly necessary for medical applications.
- Self-adhesive compositions in which the ratio of the viscous component to the elastic component at a frequency of 100 rad / s at 25 ° C. is greater than 0.7 are preferred, or self-adhesive compositions in which the ratio of the viscous component to the elastic component at a frequency of 0.1 rad / s at 25 ° C is less than 0.4, preferably between 0.35 and 0.02, very particularly preferably between 0.3 and 0.1.
- the adhesive is partially applied to the backing material, for example by screen printing, screen printing, thermoflexo printing or gravure printing, because backing materials with a full line of adhesive can cause mechanical skin irritation under unfavorable conditions when applied and are in generally not permeable to air and water vapor.
- the application is preferred in the form of polygeometric domes and very particularly of domes in which the ratio of diameter to height is less than 5: 1.
- other shapes and patterns can also be printed on the carrier material, for example a printed image in the form of alphanumeric character combinations or patterns such as grids, stripes and zigzag lines.
- the adhesive can be evenly distributed on the backing material, but it can also be applied in different thicknesses or densities over the surface in a manner that is functional for the product.
- thermal screen printing is the use of a rotating, heated, seamless, drum-shaped perforated round stencil, which is fed with the preferred hot melt self-adhesive via a nozzle.
- a specially shaped nozzle lip (round or square squeegee) presses the hot-melt adhesive fed through a channel through the perforation of the stencil wall onto the carrier web. This is guided against the outer jacket of the heated sieve drum at a speed which corresponds to the speed of rotation of the rotating sieve drum.
- the small adhesive spheres are formed according to the following mechanism:
- the nozzle doctor blade pressure conveys the hot melt adhesive through the perforated screen to the carrier material.
- the size of the spherical caps is determined by the diameter of the sieve hole.
- the sieve is lifted off the carrier in accordance with the transport speed of the carrier web (rotational speed of the sieve drum). Due to the high adhesion of the adhesive and the internal cohesion of the hotmelt, the limited supply of hotmelt adhesive in the holes is subtracted from the base of the calottes already adhering to the contour, or is conveyed onto the carrier by the squeegee pressure.
- the more or less strongly curved surface of the spherical cap forms over the predetermined base area.
- the ratio of the height to the base of the calotte depends on the ratio of the hole diameter to the wall thickness of the sieve drum and the physical properties (flow behavior, surface tension and wetting angle on the backing material) of the self-adhesive.
- the web / hole ratio can be less than 3: 1, preferably less than or equal to 1: 1, in particular equal to 1: 3.
- the described mechanism of formation of the calottes preferably requires absorbent or at least wettable carrier materials that can be wetted by hot-melt adhesive.
- Non-wetting support surfaces must be pretreated using chemical or physical processes. This can be done by additional measures such as corona discharge or coating with substances that improve wetting.
- the size and shape of the domes can be defined in a defined manner using the printing process shown.
- the adhesive strength values relevant for the application, which determine the quality of the products produced, are within very narrow tolerances when properly coated.
- the base diameter of the spherical caps can be selected from 10 ⁇ m to 5000 ⁇ m, the height of the spherical caps from 20 ⁇ m to approx. 2000 ⁇ m, preferably 50 ⁇ m to 1000 ⁇ m, the range of small diameters for smooth supports, that of a larger diameter and larger spherical cap height is intended for rough or highly porous substrates.
- the positioning of the domes on the carrier is defined by the geometry of the application, which can be varied within wide limits, for example engraving or screen geometry. With the help of the parameters shown, the desired property profile of the coating can be set very precisely, adjusted to the different carrier materials and applications.
- the carrier material is preferably coated at a speed of greater than 2 m / min, preferably 20 to 200 m / min, the coating temperature being chosen to be greater than the softening temperature.
- the self-adhesive composition can be applied to the backing material with a weight per unit area of greater than 15 g / m 2 , preferably between 90 g / m 2 and 500 g / m 2 , very particularly preferably between 130 g / m 2 and 500 g / m 2 .
- the percentage of the surface coated with the self-adhesive composition should be at least 20% and can range up to approximately 95%, for special products preferably 40% to 60% and 70% to 95%. This can optionally be achieved by multiple application, it also being possible, where appropriate, to use self-adhesive compositions with different properties.
- the combination of the preferred hot melt adhesive and the preferred partial coating ensures, on the one hand, that the medical product adheres securely to the skin, on the other hand, at least visually recognizable allergic or mechanical skin irritations are ruled out, even in the case of an application which spans several Days.
- the hot melt adhesive can be applied directly or first applied to an auxiliary carrier and then transferred to the final carrier.
- Subsequent calendering of the coated product and / or pretreatment of the carrier, such as corona radiation, for better anchoring of the adhesive layer can also be advantageous.
- the hotmelt adhesive with electron beam postcrosslinking or UV radiation can lead to an improvement in the desired properties.
- the self-adhesive compositions are foamed before they are applied to the backing material.
- the self-adhesive compositions are preferably foamed with inert gases such as nitrogen, carbon dioxide, noble gases, hydrocarbons or air or mixtures thereof.
- inert gases such as nitrogen, carbon dioxide, noble gases, hydrocarbons or air or mixtures thereof.
- foaming through thermal decomposition of gas-evolving substances such as azo, carbonate and hydrazide compounds has also proven to be suitable.
- the degree of foaming i.e. the gas content should be at least about 5% by volume and can range up to about 85% by volume. In practice, values from 10% by volume to 75% by volume, preferably 50% by volume, have proven successful. If you work at relatively high temperatures of around 100 ° C and a comparatively high internal pressure, very open-pored layers of adhesive foam are created that are particularly well permeable to air and water vapor.
- the advantageous properties of the foamed self-adhesive coatings such as low adhesive consumption, high tack and good conformability even on uneven surfaces due to the elasticity and plasticity as well as the Initiaitack can be used particularly well in the field of medical products.
- thermoplastic self-adhesive under high pressure at a temperature above the softening point (about 120 ° C) with the gases provided, such as nitrogen, air or carbon dioxide in different volume fractions (about 10 vol .-% to 80 vol .-%) in implemented a stator / rotor system.
- the mixed pressures gas / thermoplastic in the system are 40 to 100 bar, preferably 40 to 70 bar.
- the PSA foam produced in this way can then reach the application plant via a line.
- Commercial nozzles, extruder or chamber systems are used in the application. Due to the foaming of the self-adhesive and the resulting open pores in the mass, the products coated with the adhesive are well permeable to water vapor and air when using a porous carrier. The amount of adhesive required is significantly reduced without impairing the adhesive properties.
- the adhesives have a surprisingly high tack because there is more volume per gram of mass and thus the adhesive surface available for wetting the surface to be adhered and the plasticity of the adhesives is increased by the foam structure. This also improves anchorage on the carrier material.
- the foamed adhesive coating gives the products a soft and supple feel.
- Foaming also generally lowers the viscosity of the adhesive. As a result, the melting energy is reduced and thermally unstable carrier materials can also be coated directly.
- the carrier material coated with the adhesive can have an air permeability of greater than 1 preferably greater than 15 very particularly preferably greater than 70 cm ⁇ cm ⁇ s), furthermore have a water vapor permeability of greater than 500 g / (m 2 * 24h), preferably greater than 1000 g / (m 2 * 24h), very particularly preferably greater than 2000 g / ( m * 24h).
- the carrier material can also be provided with other equipment or treatments. These include, for example, corona, flame or plasma pretreatments to increase the anchoring of the self-adhesive on the base fleece. Calendering the backing material or the nonwoven not yet equipped with self-adhesive is also an advantageous treatment for the purpose of further strengthening or improving the anchoring of the self-adhesive.
- the backing material on the side opposite to the side coated with self-adhesive composition can be equipped with a water-repellent layer or impregnation, which enables rapid wetting upon contact with water or Prevents sweat.
- this can also be done by sewing on a film, advantageously a water vapor permeable film, directly when the nonwoven is solidified by sewing threads.
- the backing material can also be equipped with a release layer or impregnation and / or varnish that reduces the adhesive strength of the self-adhesive composition.
- a film advantageously a water vapor permeable film, can be sewn on directly when the nonwoven is consolidated.
- the lamination of the nonwoven backing with at least one additional layer of foams or foils has also turned out to be advantageous, since this results in a combination of special properties.
- a foam has a much higher damping property than a non-laminated carrier.
- films can be used to seal the surface.
- the carrier material can be vaporized with metallic substances.
- the carrier material can be covered with an adhesive-repellent carrier material, such as siliconized paper, or provided with a wound dressing or padding.
- the carrier material is sterilizable, preferably ⁇ - (gamma) sterilizable.
- sterilizable preferably ⁇ - (gamma) sterilizable.
- hot melt adhesives based on block copolymers that do not contain double bonds are particularly suitable for subsequent sterilization. This applies in particular to styrene-butylene-ethylene-styrene block copolymers or styrene-butylene-styrene block copolymers. There are no significant changes in the adhesive properties for the application.
- the carrier material according to the invention has an adhesive force on the back of the carrier of at least 0.5 N / cm, in particular an adhesive force between 2.5 N / cm and 5 N / cm. Higher adhesive strengths can be achieved on other substrates.
- the carrier materials according to the invention which are thus essentially inelastic, can be used for special medical purposes, and carrier materials whose use has hitherto failed due to insufficient strength and / or excessive elongation can also be used.
- Backing materials based on woven, knitted, non-woven or composite products can preferably be used, provided that they otherwise meet the requirements for medical use.
- a preferred carrier material is described below by way of example, without wishing to restrict the invention unnecessarily.
- a non-woven fabric based on viscose was used as the carrier material.
- the nonwoven fabric was sewn over with a polyester thread, the number of sewing threads being 22 / cm sample width.
- the water absorption of the polyester thread was 0.3%.
- the carrier material was calendered and impregnated.
- the carrier material thus produced had a maximum tensile force of 50 N / cm in the longitudinal direction and a maximum tensile force elongation of 28%.
- the weight per unit area was 120 g / cm 2 .
- Complete wetting of the backing material was not possible due to the selection of the reinforcement materials.
- the carrier material has a thickness of 1.0 mm when unloaded, which produces a good cushioning effect.
- the carrier material had an air permeability of 100 cnrVfcn ⁇ s) and water vapor permeability of more than 2500 g / (m 2 * 24h) and could be torn and torn by hand in the transverse and longitudinal directions.
- the hot melt adhesive was applied to the backing using thermal screen printing.
- the hot melt adhesive composition was as follows:
- an A-B / A-B-A block copolymer consisting of hard and soft segments with a ratio of A-B-A to A-B of 2: 1 and a styrene content in the polymer of 13 mol%;
- the proportion of the adhesive is 40% by weight (Kraton G), a paraffin hydrocarbon wax with a proportion of the adhesive of 51% by weight,
- Hydrocarbon resins with a share of 7.5% by weight (Super Resin HC 140), an anti-aging agent with a share of less than 0.5% by weight (Irganox). a hyperemic active ingredient (nonanonyl vanillylamid); 1% share.
- the components used were homogenized in a thermal mixer at 125 ° C. The glass transition was -9 ° C according to the above method.
- Direct coating was carried out at 50 m / min at a temperature of 120 ° C.
- the carrier material was partially coated with 120 g / m 2 , a 14 mesh screen template with a screen thickness of 300 ⁇ m being used.
- the bandage produced by this method showed a reversible detachment from the skin and a good air and water vapor permeability. No skin irritation and negligible epilation after removal of the bandage were observed.
- the carrier material thus produced shows good release of the active ingredient.
- a non-woven fabric based on viscose was used as the carrier material.
- the nonwoven fabric was sewn over with a polyamide thread, the number of sewing threads being 7 / cm sample width.
- the carrier material was calendered and impregnated.
- the carrier material produced in this way had a maximum tensile force of 12 N / cm in the longitudinal direction and a maximum tensile force elongation of 28%.
- the weight per unit area was 140 g / cm 2 .
- Complete wetting of the backing material was not possible due to the selection of the reinforcement materials.
- the carrier material has an unloaded thickness of 1.2 mm, which creates a good cushioning effect.
- the carrier material had an air permeability core of 80 and water vapor permeability of more than 2500 g / (m 2 * 24h) and could be torn and torn by hand in the transverse and longitudinal directions.
- This hotmelt PSA was composed as follows: a SEPS block copolymer consisting of hard and soft segments and a styrene content in the polymer of 13 mol%; the proportion of the adhesive is 15% by weight (Kuraray Co.) a paraffin hydrocarbon resin with a proportion of 44% by weight of the adhesive, an anti-aging agent with a proportion of less than 1.0% by weight (Irganox
- the adhesive components used were homogenized in a thermal mixer at 185 ° C 3.5.
- the active ingredient was added in the cooling phase at 120 ° C. and homogenized in the mixer for a further 130 min.
- the softening point of this adhesive was approximately 85 ° C. (DIN 52011), and the adhesive showed a viscosity of 2100 mPas at 150 ° C. (DIN 53018, Brookfield DV II, column 21). According to the above, the glass transition was Method - 10 ° C.
- the self-adhesive was applied to the entire surface with a nozzle.
- the direct coating was carried out at 50 m min at a temperature of 120 ° C.
- the carrier material was coated with 170 g / m 2 .
- the plaster material produced in this way shows a comparably good release of the active ingredient.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Materials Engineering (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
- Chemical Or Physical Treatment Of Fibers (AREA)
- Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU25217/99A AU752378B2 (en) | 1998-02-06 | 1999-02-04 | Supporting material for medicinal purposes |
DE59903247T DE59903247D1 (en) | 1998-02-06 | 1999-02-04 | CARRIER MATERIAL FOR MEDICAL PURPOSES |
EP99904855A EP1053030B1 (en) | 1998-02-06 | 1999-02-04 | Supporting material for medicinal purposes |
AT99904855T ATE226833T1 (en) | 1998-02-06 | 1999-02-04 | BACKING MATERIAL FOR MEDICAL PURPOSES |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19804774.6 | 1998-02-06 | ||
DE19804774A DE19804774A1 (en) | 1998-02-06 | 1998-02-06 | Substrates for medical purposes |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1999039756A2 true WO1999039756A2 (en) | 1999-08-12 |
WO1999039756A3 WO1999039756A3 (en) | 1999-09-23 |
Family
ID=7856862
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1999/000738 WO1999039756A2 (en) | 1998-02-06 | 1999-02-04 | Supporting material for medicinal purposes |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1053030B1 (en) |
AT (1) | ATE226833T1 (en) |
AU (1) | AU752378B2 (en) |
DE (2) | DE19804774A1 (en) |
ES (1) | ES2185317T3 (en) |
WO (1) | WO1999039756A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000013679A1 (en) * | 1998-09-03 | 2000-03-16 | Lts Lohmann Therapie-Systeme Ag | Plaster containing a medicament, with three functional layers |
US20210007899A1 (en) * | 2018-04-02 | 2021-01-14 | Marine Biology & Environmental Technologies, Llc | Medical dressings and uses therof |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19921743A1 (en) * | 1999-05-11 | 2000-11-16 | Beiersdorf Ag | Cohesive carrier material |
DE10020102A1 (en) * | 2000-04-22 | 2001-10-25 | Beiersdorf Ag | Procedure for partial application of high viscosity fluids to base material entails using nozzle with geometry such that at mouth of nozzle's fluid discharge gap a pressure increase takes place |
DE10032537A1 (en) * | 2000-07-05 | 2002-01-31 | Labtec Gmbh | Dermal system containing 2- (3-benzophenyl) propionic acid |
ITTV20020008A1 (en) * | 2002-01-25 | 2003-07-25 | Al Pre Tec S R L Allergy Preve | PROCEDURE FOR OBTAINING A SILK MANUFACTURE INDICATED IN THE TREATMENT OF CERTAIN SKIN AFFECTIONS OF THE HUMAN BODY |
DE10207776A1 (en) * | 2002-02-23 | 2003-09-04 | Tesa Ag | Process for the production of a partially coated plaster |
DE10236319A1 (en) * | 2002-08-08 | 2004-02-19 | Beiersdorf Ag | Active agent containing matrix plaster for the controlled delivery of an active agent to the skin comprises a pharmaceutical active agent containing a water insoluble adhesive matrix comprising a styrene block copolymer |
DE20216598U1 (en) | 2002-10-23 | 2003-03-20 | Dehn, Michael C., 20099 Hamburg | Wart-removing product comprises an air-impermeable covering |
DE10306187B4 (en) * | 2003-02-13 | 2005-08-04 | Steffen Barth | plaster |
DE102004058140B4 (en) * | 2004-11-25 | 2007-09-20 | Tesa Ag | Hydroactive plaster with three-dimensional tangle coating |
US20070179461A1 (en) * | 2006-02-02 | 2007-08-02 | Bristol-Myers Squibb Company | Hot-melt silicone based ostomy and wound care skin attachment adhesives |
DE102011081818A1 (en) * | 2011-08-30 | 2013-02-28 | Beiersdorf Ag | Active skin coatings |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4967740A (en) * | 1986-06-11 | 1990-11-06 | Minnesota Mining And Manufacturing Company | Dispensable tapes |
DE4224325C1 (en) * | 1992-07-23 | 1994-02-10 | Sanol Arznei Schwarz Gmbh | Active ingredient plasters for low-melting and / or volatile active ingredients and process for its manufacture |
DE4237252A1 (en) * | 1992-11-04 | 1994-05-05 | Zweckform Buero Prod Gmbh | Flexible, removable, residue-free removable fabric, process for its production and its use |
US5453319A (en) * | 1992-05-18 | 1995-09-26 | Minnesota Mining And Manufacturing Company | Hot-melt-coatable adhesives |
DE4442092A1 (en) * | 1994-11-25 | 1996-05-30 | Beiersdorf Ag | Backside coated adhesive tape based on sewing fleece |
DE19531291A1 (en) * | 1995-08-25 | 1997-02-27 | Beiersdorf Ag | Substrates for medical purposes |
DE19631422A1 (en) * | 1996-08-06 | 1998-02-12 | Beiersdorf Ag | Carrier materials equipped with self-adhesive |
-
1998
- 1998-02-06 DE DE19804774A patent/DE19804774A1/en not_active Withdrawn
-
1999
- 1999-02-04 AU AU25217/99A patent/AU752378B2/en not_active Ceased
- 1999-02-04 ES ES99904855T patent/ES2185317T3/en not_active Expired - Lifetime
- 1999-02-04 DE DE59903247T patent/DE59903247D1/en not_active Expired - Lifetime
- 1999-02-04 AT AT99904855T patent/ATE226833T1/en not_active IP Right Cessation
- 1999-02-04 EP EP99904855A patent/EP1053030B1/en not_active Expired - Lifetime
- 1999-02-04 WO PCT/EP1999/000738 patent/WO1999039756A2/en active IP Right Grant
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4967740A (en) * | 1986-06-11 | 1990-11-06 | Minnesota Mining And Manufacturing Company | Dispensable tapes |
US5453319A (en) * | 1992-05-18 | 1995-09-26 | Minnesota Mining And Manufacturing Company | Hot-melt-coatable adhesives |
DE4224325C1 (en) * | 1992-07-23 | 1994-02-10 | Sanol Arznei Schwarz Gmbh | Active ingredient plasters for low-melting and / or volatile active ingredients and process for its manufacture |
DE4237252A1 (en) * | 1992-11-04 | 1994-05-05 | Zweckform Buero Prod Gmbh | Flexible, removable, residue-free removable fabric, process for its production and its use |
DE4442092A1 (en) * | 1994-11-25 | 1996-05-30 | Beiersdorf Ag | Backside coated adhesive tape based on sewing fleece |
DE19531291A1 (en) * | 1995-08-25 | 1997-02-27 | Beiersdorf Ag | Substrates for medical purposes |
DE19631422A1 (en) * | 1996-08-06 | 1998-02-12 | Beiersdorf Ag | Carrier materials equipped with self-adhesive |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000013679A1 (en) * | 1998-09-03 | 2000-03-16 | Lts Lohmann Therapie-Systeme Ag | Plaster containing a medicament, with three functional layers |
US20210007899A1 (en) * | 2018-04-02 | 2021-01-14 | Marine Biology & Environmental Technologies, Llc | Medical dressings and uses therof |
Also Published As
Publication number | Publication date |
---|---|
ES2185317T3 (en) | 2003-04-16 |
AU2521799A (en) | 1999-08-23 |
WO1999039756A3 (en) | 1999-09-23 |
EP1053030A2 (en) | 2000-11-22 |
ATE226833T1 (en) | 2002-11-15 |
DE19804774A1 (en) | 1999-08-12 |
DE59903247D1 (en) | 2002-12-05 |
AU752378B2 (en) | 2002-09-19 |
EP1053030B1 (en) | 2002-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE19746913C2 (en) | Substrates for medical purposes | |
EP0914820B1 (en) | Plasters containing active agents having a partially applied adhesive composition | |
EP0918080B1 (en) | Carrier with discontinuous self-adhesive coating | |
EP0901357B1 (en) | Air-permeable substrate material partially coated with a self-adhesive substance, process for its production and its use | |
EP0890366B1 (en) | Carrier for medical uses | |
EP1053030B1 (en) | Supporting material for medicinal purposes | |
EP1085914B1 (en) | Plaster containing an active agent | |
WO1999057354A1 (en) | Supporting material for medical purposes | |
DE19650471A1 (en) | Patches containing active ingredient | |
EP1052979B1 (en) | Device for releasing substances | |
WO2006018340A1 (en) | Active agent-containing plaster strip for treating joint diseases | |
WO2000068334A1 (en) | Support material with a cohesive adhesive substance | |
EP1177836B1 (en) | Process for applying hot melt adhesives on a carrier | |
DE10110953A1 (en) | Transdermal therapeutic system for the administration of partial dopamine D2 agonists | |
DE102006004480A1 (en) | Surgical wound dressing has a first layer of bare polyacrylate fibers in contact with the wound | |
EP1098023A1 (en) | Self adhesive fabric |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 25217/99 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999904855 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09601029 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1999904855 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1999904855 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 25217/99 Country of ref document: AU |